TOday’s Movers: Global Blood Therapeutics (GBT) Stock Rating Maintained by Analysts at Oppenheimer; $53.0 Target Price Indicates -2.93 % Potential

January 19, 2018 - By reb123z

 TOday’s Movers: Global Blood Therapeutics (GBT) Stock Rating Maintained by Analysts at Oppenheimer; $53.0 Target Price Indicates  2.93 % Potential

Global Blood Therapeutics (GBT) Rating Reaffirmed

The firm has just set a TP of $53.0 on Global Blood Therapeutics (GBT) shares. This is -2.93 % from the previous stock close. In a research note shared with investors and clients on Monday morning, Oppenheimer kept their “Buy” rating on shares of GBT.

Global Blood Therapeutics Inc. (NASDAQ:GBT) Ratings Coverage

Among 14 analysts covering Global Blood T… (GBT), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Global Blood T… has $91.0 highest and $37 lowest target. $64.92’s average target is 18.90% above currents $54.6 stock price. Global Blood T… had 35 analyst reports since April 20, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Friday, June 17 by Empire. The firm earned “Buy” rating on Monday, December 11 by H.C. Wainwright. Needham maintained Global Blood Therapeutics Inc. (NASDAQ:GBT) on Thursday, December 14 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Tuesday, November 1. Oppenheimer maintained Global Blood Therapeutics Inc. (NASDAQ:GBT) on Thursday, January 11 with “Buy” rating. Oppenheimer maintained Global Blood Therapeutics Inc. (NASDAQ:GBT) rating on Monday, October 30. Oppenheimer has “Buy” rating and $53.0 target. The company was maintained on Monday, December 11 by Cantor Fitzgerald. As per Thursday, January 11, the company rating was maintained by H.C. Wainwright. The company was maintained on Thursday, January 11 by Cowen & Co. The stock of Global Blood Therapeutics Inc. (NASDAQ:GBT) earned “Buy” rating by Oppenheimer on Friday, September 1.

The stock increased 3.02% or $1.6 during the last trading session, reaching $54.6. About 165,781 shares traded. Global Blood Therapeutics Inc. (GBT) has risen 43.51% since January 19, 2017 and is uptrending. It has outperformed by 26.81% the S&P500.

Analysts await Global Blood Therapeutics Inc. (NASDAQ:GBT) to report earnings on March, 12. They expect $-0.73 EPS, up 1.35 % or $0.01 from last year’s $-0.74 per share. After $-0.66 actual EPS reported by Global Blood Therapeutics Inc. for the previous quarter, Wall Street now forecasts 10.61 % negative EPS growth.

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders. The company has market cap of $2.51 billion. The Company’s lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. It currently has negative earnings. The firm is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities.

More important recent Global Blood Therapeutics Inc. (NASDAQ:GBT) news were published by: Seekingalpha.com which released: “ROTY Edition 1 Volume 69: BTD For Global Blood Therapeutics And Other Updates” on January 10, 2018, also Streetinsider.com published article titled: “Global Blood Therapeutics (GBT) Announces FDA Breakthrough Therapy Designation …”, Seekingalpha.com published: “Global Blood Therapeutics: What The Recent FDA Breakthrough Therapy …” on January 14, 2018. More interesting news about Global Blood Therapeutics Inc. (NASDAQ:GBT) was released by: Prnewswire.com and their article: “Technical Perspectives on Agenus, Coherus Biosciences, Global Blood …” with publication date: January 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: